stockrow
Friday 6 November 2026
Export PRFX’s income statement to Excel — free account
PainReform Ltd.
PRFX Healthcare Drug Manufacturers Specialty & Generic
PainReform Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17,000.00.
0.83
0.07
+9.21%
Follow PRFX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | 0 | — | — | 11 | 11 | — | +2,446.0% | |
| Gross margin, % | — | — | — | 0.00 | — | 0.00 | 0.00 | — | — | (311.76) | 0.00 | (311.8) pt | ||||||
| EBT | — | — | (1) | (1) | (4) | (7) | (9) | (9) | (15) | (5) | (10) | +29.3% | ||||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (29,494.12) | 0.00 | (29,494.1) pt | ||||||
| Net income | — | 0 | (1) | (1) | (4) | (7) | (9) | (9) | (15) | (5) | (18) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.00 | n/m | |||||
| Earnings | — | — | (2,415.99) | (2,659.43) | (1,499.70) | (887.82) | (983.80) | (122.94) | (105.52) | (7.47) | (1,191.67) | (56.2%) | ||||||
| Cash flow | — | — | (818.65) | (1,218.00) | (947.04) | (799.15) | (717.67) | (87.88) | (91.26) | (6.10) | 0.00 | (50.3%) | ||||||
| Capex | — | — | 0.00 | 0.00 | (3.70) | (6.10) | (0.67) | (0.12) | (0.09) | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | (818.65) | (1,218.00) | (950.74) | (805.24) | (718.33) | (87.99) | (91.35) | (6.11) | 0.00 | (50.3%) | ||||||
| Book value | — | — | (5,746.00) | (11,244.00) | 6,155.56 | 2,205.12 | 1,224.56 | 95.24 | 13.19 | 14.34 | 0.00 | n/m | ||||||
| Shares, m | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | +161.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | 0.01 | 0.00 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | 0.20 | 0.86 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (1) | (1) | (3) | (7) | (6) | (7) | (13) | (4) | (13) | +29.9% | |||||
| Capex | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (27.5%) | ||||||
| Free cash flow | — | — | (1) | (1) | (3) | (7) | (6) | (7) | (13) | (4) | (13) | +29.9% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | 0 | (5) | 17 | 18 | 11 | 7 | 2 | 2 | 10 | +63.2% | |||||
| Net debt | — | — | 4 | 5 | (16) | (17) | (10) | (8) | (4) | (4) | (12) | n/m | ||||||
| Shareholders’ equity | — | — | (4) | (6) | 17 | 18 | 11 | 7 | 2 | 9 | 16 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | (4,627.16) | (205.46) | (42.74) | (39.30) | (56.00) | (83.96) | (201.84) | (60.79) | 0.00 | +4,566.4 pt | |||||
| ROIC | — | — | 0.00 | 0.00 | (112.30) | (298.15) | (667.85) | 0.00 | 0.00 | (62.48) | 0.00 | (62.5) pt | ||||||
| ROE | — | — | 16.07 | 10.97 | (185.20) | (41.76) | (60.42) | (102.34) | (321.92) | (90.37) | 0.00 | (106.4) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | 3 | 2 | 4 | 6 | 7 | 6 | 7 | — | +15.2% | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · fundamentals updated 26 Oct 2026
PainReform Ltd. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| YCBD cbdMD, Inc. | $4.4M | — (loss-making) | — (loss-making) | +20.55% (above 0%: growing) | n/m | +34.80% (above 0%: growing) | 54.69% | (20.36%) | Compare |
| APUS Apimeds Pharmaceuticals US, Inc. | $4.1M | — (loss-making) | — | — | n/m | −67.94% (below 0%: shrinking) | — | 0.00% | Compare |
| RDHL Redhill Biopharma Ltd. | $3.8M | — (loss-making) | — (loss-making) | −90.32% (below 0%: shrinking) | n/m | −107.31% (below 0%: shrinking) | (7.52%) | 0.00% | Compare |
| PRFX PainReform Ltd. | $2.3M | — (loss-making) | — (loss-making) | — | n/m | +52.56% (above 0%: growing) | 0.00% | 0.00% | |
| BTAIQ BioXcel Therapeutics, Inc. | $2.3M | — (loss-making) | — (loss-making) | +51.67% (above 0%: growing) | n/m | +51.51% (above 0%: growing) | 87.91% | (5,600.55%) | Compare |
| AKAN Akanda Corp. | $2.2M | — | — | — | — | −472.01% (below 0%: shrinking) | (197.87%) | 0.00% | Compare |
| SBFM Sunshine Biopharma, Inc. | $2.1M | — (loss-making) | — (loss-making) | −1.56% (below 0%: shrinking) | n/m | +49.38% (above 0%: growing) | 26.20% | (17.41%) | Compare |
| SXTC China SXT Pharmaceuticals, Inc. | $2.0M | — (loss-making) | — (loss-making) | −16.76% (below 0%: shrinking) | +92.67% (above 0%: growing) | −107.59% (below 0%: shrinking) | 44.09% | 0.00% | Compare |
| IMCC IM Cannabis Corp. | $980.0K | — (loss-making) | — (loss-making) | −40.28% (below 0%: shrinking) | n/m | −266.81% (below 0%: shrinking) | 19.83% | (27.54%) | Compare |
| Median of peers | $2.3M | — | — | −9.16% | — | −87.62% | 26.20% | (8.70%) |